VER-49009 (Synonyms: CCT 129397)

Cat. No.: HY-15986 Purity: 99.45%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

VER-49009 is a Hsp90 inhibitor, with an IC₅₀ of 25 nM and a K_d of 78 nM.

For research use only. We do not sell to patients.

VER-49009 Chemical Structure

CAS No. : 558640-51-0

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 102	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 102	In-stock	Estimated Time of Arrival: December 31
Solid
2 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 190	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 550	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 750	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSP Isoform Specific Products:

View All Isoforms

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

VER-49009 is a Hsp90 inhibitor, with an IC₅₀ of 25 nM and a K_d of 78 nM.

IC₅₀ & Target^[1]

HSP90

25 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	GI₅₀	1.2 μM Compound: 6, VER-49009	Growth inhibition of human DU145 cells by SRB assay Growth inhibition of human DU145 cells by SRB assay	[PMID: 18020435]
HCT-116	GI₅₀	0.26 μM Compound: 6, VER-49009	Growth inhibition of human HCT116 cells after 24 hrs by SRB assay Growth inhibition of human HCT116 cells after 24 hrs by SRB assay	[PMID: 18020435]
NCI-H1975	GI₅₀	1 μM Compound: 2, VER-49009	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells after 1 to 3 days by MTS assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells after 1 to 3 days by MTS assay	[PMID: 24345447]
PC-3M	GI₅₀	2.2 μM Compound: 6, VER-49009	Growth inhibition of human PC3M cells by SRB assay Growth inhibition of human PC3M cells by SRB assay	[PMID: 18020435]
SF-268	GI₅₀	0.32 μM Compound: 6, VER-49009	Growth inhibition of human SF268 cells by SRB assay Growth inhibition of human SF268 cells by SRB assay	[PMID: 18020435]
SK-BR-3	EC₅₀	0.35 μM Compound: 3, VER-49009	Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis	[PMID: 21106457]
SK-BR-3	EC₅₀	0.5 μM Compound: 3, VER-49009	Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis	[PMID: 21106457]
SK-MEL-28	GI₅₀	0.48 μM Compound: 6, VER-49009	Growth inhibition of human SKMel28 cells by SRB assay Growth inhibition of human SKMel28 cells by SRB assay	[PMID: 18020435]
U-87MG ATCC	GI₅₀	1.2 μM Compound: 6, VER-49009	Growth inhibition of human U87MG cells by SRB assay Growth inhibition of human U87MG cells by SRB assay	[PMID: 18020435]

In Vitro

VER-49009 is a Hsp90 inhibitor, with an IC₅₀ of 25 nM. VER-49009 binds to the ATPase of full length yeast Hsp90 protein, with an IC₅₀ of 140 nM^[1]. VER-49009 inhibits Hsp90, with a K_d of 78 nM. VER-49009 also shows antiproliferative activities against various human cancer cells, with a mean GI₅₀ of 685 ± 119 nM. VER-49009 suppressses the proliferation of human umbilical vein endothelial cells (HUVEC) with GI₅₀ values of 444 ± 91.1 nM, and shows higher GI₅₀s against nontumorigenic human breast (MCF10a) and prostate (PNT2) epithelial cells. VER-49009 displays no differences in cellular activities of isogenic cell lines, and these activities are independent of NQO1 expression^[2]. VER-49009 inhibits the proliferation (1, 2.5 μM), induces G2 phase arrest and reduces total Akt and phospho-Akt expression levels in CFSC cells (1-5 μM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

VER-49009 (4 mg/kg, i.p.) results in clear depletion of ERBB2 at 3 and 8 h following the final dose, with client protein levels returning to normal by 24 h, in the athymic mice bearing well-established OVCAR3 human ovarian ascites tumors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

387.82

Formula

C₁₉H₁₈ClN₃O₄

CAS No.

558640-51-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=NNC(C2=CC(Cl)=C(O)C=C2O)=C1C3=CC=C(OC)C=C3)NCC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (257.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5785 mL	12.8926 mL	25.7852 mL
5 mM	0.5157 mL	2.5785 mL	5.1570 mL
10 mM	0.2579 mL	1.2893 mL	2.5785 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (7.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.75 mg/mL (7.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.45%

Select Batch:

Data Sheet (283 KB) SDS (251 KB)

COA (260 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Dymock BW, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5. [Content Brief]

[2]. Sharp SY, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007 Apr;6(4):1198-211. [Content Brief]

[3]. Sun X, et al. Inhibition of hepatic stellate cell proliferation by heat shock protein 90 inhibitors in vitro. Mol Cell Biochem. 2009 Oct;330(1-2):181-5. [Content Brief]

Cell Assay ^[3]	Briefly, 5 × 10³ cells/well are plated in 96-well culture plates. After an overnight incubation, the cells are treated with various concentrations of VER-49009 and VER-49009M (0, 1, 2.5, and 5 μM) for 24 h^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	In some studies, female NCr athymic mice are implanted i.p. with 10 million OVCAR3 ovarian carcinoma cells harvested from donor mice. This tumor mimics late-stage malignant disease. Once tumors are well established, mice are injected i.p. with 4 mg/kg VER-49009 or VER-50589 twice daily over 2 days (four doses total). Tumors are harvested at intervals after the last dose and snap frozen for pharmacodynamic analyses^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Dymock BW, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5. [Content Brief] [2]. Sharp SY, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007 Apr;6(4):1198-211. [Content Brief] [3]. Sun X, et al. Inhibition of hepatic stellate cell proliferation by heat shock protein 90 inhibitors in vitro. Mol Cell Biochem. 2009 Oct;330(1-2):181-5. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5785 mL	12.8926 mL	25.7852 mL	64.4629 mL
	5 mM	0.5157 mL	2.5785 mL	5.1570 mL	12.8926 mL
	10 mM	0.2579 mL	1.2893 mL	2.5785 mL	6.4463 mL
	15 mM	0.1719 mL	0.8595 mL	1.7190 mL	4.2975 mL
	20 mM	0.1289 mL	0.6446 mL	1.2893 mL	3.2231 mL
	25 mM	0.1031 mL	0.5157 mL	1.0314 mL	2.5785 mL
	30 mM	0.0860 mL	0.4298 mL	0.8595 mL	2.1488 mL
	40 mM	0.0645 mL	0.3223 mL	0.6446 mL	1.6116 mL
	50 mM	0.0516 mL	0.2579 mL	0.5157 mL	1.2893 mL
	60 mM	0.0430 mL	0.2149 mL	0.4298 mL	1.0744 mL
	80 mM	0.0322 mL	0.1612 mL	0.3223 mL	0.8058 mL
	100 mM	0.0258 mL	0.1289 mL	0.2579 mL	0.6446 mL

VER-49009 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

VER-49009558640-51-0CCT 129397VER49009VER 49009CCT129397CCT-129397HSPHeat shock proteinsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks